Biocon, a Bangalore based leading biotech company, has launched Basalog, a long acting peak less human insulin analogue, Glargine in India for type-I & II diabetics and has signed an agreement with Bayer Polychem (India) for marketing and distribution of their advanced No Coding technology blood glucose monitoring system, 'Breeze 2' with their insulin product portfolio.

Basalog is a significant advance in diabetic treatment which is effective for 24 hours while continuing to maintain the basal level of insulin required throughout the period thus helping to control glucose levels in the blood, especially fasting plasma glucose.

Breeze 2 will help ease monitoring of blood glucose levels with a more convenient system of a disc containing 10 strips which needs to be loaded just once. The patient can then carry out 10 tests thus avoiding the need to load individual strips each time. This ensures better compliance and facilitates regular blood sugar checks.

Kiran Mazumdar Shaw, chairman and managing director, said, "Diabetes is a debilitating disease that is pervading global populations like a pandemic with India at its epicenter. Biocon is committed to developing affordable insulin based therapies to manage this disease burden. Basalog, a peak less long acting insulin analog, augments the efficacy of recombinant human insulin and it is our endeavour to play a key role in combating diabetes the world over."

Rakesh Bamzai, president marketing, said, "Biocon's research efforts over the years have yielded many important bio-therapeutics for diabetes and other life threatening diseases. Glargine is truly a life changing drug for diabetes management that has been delivered from our R&D pipeline which will be an enormous boon to diabetic patients in India. What is even more important is the affordable pricing which Biocon brings to the Indian market which will provide greater access to such a vital drug."